Brevan Howard

Many macro funds, which have struggled over the past few years, were taken by surprise when the post-election trades that had finally given them a boost in the fourth quarter reversed direction this year.
The troubled pharmaceutical company, a big holding of hedge fund ValueAct, continues its downward trajectory.
The British hedge fund firm won an injunction to stop the wire service from publishing a story that included details Brevan Howard deemed confidential.
Macro hedge funds have seen their post-election plays reverse direction over the past six weeks.
The firm’s Wellington fund rebounded sharply from a sizable loss in the first quarter.
Macro managers posted mixed results in the wake of the U.S. presidential election in November, with some making hay and others posting declines.